Howze Yalonda 4
4 · Generation Bio Co. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Generation Bio (GBIO) Interim CEO Howze Sells Shares in Merger
What Happened
Howze Yalonda, Interim CEO and President of Generation Bio (GBIO), disposed of a total of 59,084 shares on February 9, 2026 as part of the company’s change-of-control transaction. The Form 4 reports multiple dispositions (including a change-of-control disposition of 3,759 shares and several dispositions to the issuer totaling 55,325 shares). Under the merger agreement, each tendered share was exchanged for $4.2913 in cash (total cash ≈ $253,547) plus one non-tradeable contingent value right (CVR) per share with an estimated maximum contingent value of $25.01 per CVR (aggregate potential contingent consideration ≈ $1.48M). Some outstanding options with exercise prices ≥ the cash amount were cancelled for no consideration per the merger terms.
Key Details
- Transaction date: February 9, 2026 (Effective Time of merger)
- Reported price on Form 4: listed as N/A for each line, but merger footnote discloses $4.2913 cash per share plus one CVR per share (max $25.01 per CVR)
- Shares disposed: 59,084 total (3,759 in change-of-control line; 10,710; 11,883; 25,102; 7,630 in dispositions to issuer)
- Estimated cash proceeds: ≈ $253,547; estimated maximum contingent value: ≈ $1,477,691 (not guaranteed)
- Shares owned after transaction: not specified in the filing
- Notable footnotes: transactions were part of a tender offer and subsequent merger; CVRs are non-tradeable contingent rights; certain unexercised options with exercise price ≥ $4.2913 were cancelled for no consideration.
- Filing timeliness: filed with an effective date of Feb 9, 2026; filing does not indicate a late report.
Context
These were not open-market trades but merger-related dispositions — shares were tendered/exchanged under the Merger Agreement with XOMA Royalty Corporation and its subsidiary. The CVRs represent contingent, non-tradeable future payments subject to conditions, so the maximum additional consideration is uncertain. Cancellation of certain options for no consideration is a contractual effect of the merger rather than a voluntary sale by the insider.
Insider Transaction Report
- Disposition from Tender
Common Stock
[F1][F2]2026-02-09−3,759→ 0 total - Disposition to Issuer
Stock Option (right to buy)
[F3]2026-02-09−10,710→ 0 totalExercise: $39.70→ Common Stock (10,710 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F3]2026-02-09−11,883→ 0 totalExercise: $18.60→ Common Stock (11,883 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F3]2026-02-09−25,102→ 0 totalExercise: $9.26→ Common Stock (25,102 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F3]2026-02-09−7,630→ 0 totalExercise: $13.90→ Common Stock (7,630 underlying)
Footnotes (3)
- [F1]Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
- [F2](continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- [F3]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.